Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Sana Biotechnology Inc (SANA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/13/2025: SANA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -34.56% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 384.79M USD | Price to earnings Ratio - | 1Y Target Price 9.14 |
Price to earnings Ratio - | 1Y Target Price 9.14 | ||
Volume (30-day avg) 2848280 | Beta 1.64 | 52 Weeks Range 1.49 - 10.50 | Updated Date 04/1/2025 |
52 Weeks Range 1.49 - 10.50 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.82% | Return on Equity (TTM) -99.17% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 319741830 | Price to Sales(TTM) - |
Enterprise Value 319741830 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.08 | Shares Outstanding 225024992 | Shares Floating 134139593 |
Shares Outstanding 225024992 | Shares Floating 134139593 | ||
Percent Insiders 8.58 | Percent Institutions 93.7 |
Analyst Ratings
Rating 4.14 | Target Price 9.8 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Sana Biotechnology Inc
Company Overview
History and Background
Sana Biotechnology, Inc. was founded in 2018. The company is focused on developing engineered cells as medicines for various diseases. It aims to control genes, cells, and the immune system to treat and potentially cure diseases.
Core Business Areas
- In Vivo Delivery: Developing gene therapies to deliver therapeutic genes directly into cells within the body.
- Ex Vivo Delivery: Engineering cells outside the body and then transplanting them back into the patient.
- Hypoimmune Platform: Creating cells that can evade the immune system, allowing for broader applicability of cell therapies.
Leadership and Structure
The leadership team includes Steve Harr, CEO. The organizational structure is typical of a biotechnology company, with research and development, clinical development, and manufacturing divisions.
Top Products and Market Share
Key Offerings
- SC291: Sana's lead in vivo product candidate targeting CD8+ T cells for oncology indications, including multiple myeloma and lymphoma. Currently in preclinical studies. Market share is currently zero as it is in preclinical development. Competitors include companies developing CAR-T therapies and other cancer immunotherapies.
- SC262: Sana's lead in vivo product candidate targeting B cells for autoimmune indications. Currently in preclinical studies. Market share is currently zero as it is in preclinical development. Competitors include companies developing anti-B cell therapies and other autoimmune treatments.
Market Dynamics
Industry Overview
The gene and cell therapy industry is rapidly growing, driven by advancements in technology and increasing success in treating previously incurable diseases. The industry faces challenges related to manufacturing scalability, regulatory hurdles, and high treatment costs.
Positioning
Sana aims to differentiate itself through its hypoimmune platform, which could potentially address the limitations of current cell therapies by reducing the risk of immune rejection. The company has strong financial backing but is still in early stages of clinical development.
Total Addressable Market (TAM)
The TAM for gene and cell therapies is estimated to be in the hundreds of billions of dollars. Sana is positioning itself to capture a significant share of this market through its innovative platform technologies.
Upturn SWOT Analysis
Strengths
- Innovative hypoimmune platform
- Strong financial backing
- Experienced leadership team
- Diverse pipeline of preclinical programs
Weaknesses
- Early stage of clinical development
- High cash burn rate
- Dependence on successful development of platform technologies
- Complex manufacturing processes
Opportunities
- Expanding application of cell and gene therapies
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results
- Addressing unmet medical needs in various diseases
Threats
- Regulatory hurdles
- Competition from established biotechnology companies
- Manufacturing challenges
- Potential for adverse events in clinical trials
Competitors and Market Share
Key Competitors
- CRSP
- EDIT
- BEAM
Competitive Landscape
Sana faces competition from established gene editing and cell therapy companies. Its hypoimmune platform is a key differentiator, but it needs to demonstrate clinical efficacy to gain a competitive advantage. Note that SANA has a current market share of 0 since none of its products are in the marketplace.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: As a pre-revenue company, historical growth is measured by the expansion of the pipeline and the advancement of programs into clinical trials.
Future Projections: Future growth is dependent on the successful development and commercialization of Sana's pipeline programs. Analyst estimates vary widely due to the inherent uncertainties in biotechnology.
Recent Initiatives: Recent initiatives include advancing lead product candidates into clinical trials, expanding manufacturing capabilities, and exploring partnerships.
Summary
Sana Biotechnology is an early-stage biotechnology company with a promising hypoimmune platform. The company's strengths lie in its innovative technology and strong financial resources. However, it faces significant risks associated with clinical development and competition. Successful clinical trials and strategic partnerships will be crucial for future growth.
Similar Companies
BEAM
Beam Therapeutics Inc
BEAM
Beam Therapeutics Inc
BLUE
Bluebird bio Inc
BLUE
Bluebird bio Inc
CRSP
Crispr Therapeutics AG
CRSP
Crispr Therapeutics AG
EDIT
Editas Medicine Inc
EDIT
Editas Medicine Inc
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sana Biotechnology Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2021-02-04 | President, CEO & Director Dr. Steven D. Harr M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 194 | Website https://www.sana.com |
Full time employees 194 | Website https://www.sana.com | ||
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline consist of UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SC291, a HIP-modified allogeneic CD19-dirtected allogeneic CAR T cell product candidate which is in phase 1 clinical trial to treat systemic lupus erythematosus and ANCA-associated vasculitis, as well as in preclinical trial to treat other indications and b-cell mediated autoimmune disease; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. It also develops SC262, a hypoimmune-modified CD22-directed allogeneic CAR T program, which is in phase 1 to treat non-Hodgkin's lymphoma; and SG299, a CD8-targeted fusosome, which is in preclinical trial to treat patients with hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.